Shire PLC’s constipation drug Motegrity (prucalopride) won a US FDA’s advisory committee’s unanimous endorsement Oct. 18 on the strength of reassuring cardiovascular safety data, although some panelists called for further evaluation of a potential suicidality signal.
The Gastrointestinal Drugs Advisory Committee voted 10-0 that prucalopride’s risk-benefit profile supports approval for treatment of chronic idiopathic constipation (CIC)....





